Evidence map›Paper›PMID 35219584›Full record

SynthesisCytotherapy2022

Mesenchymal stem/stromal cell-based therapies for COVID-19: First iteration of a living systematic review and meta-analysis: MSCs and COVID-19.

Aidan M Kirkham, Madeline Monaghan, Adrian J M Bailey, Risa Shorr, Manoj M Lalu, Dean A Fergusson, David S Allan

Open access · bronzeAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Cytotherapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 3 pooled it
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 3 syntheses or guidelines pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Article
  6. Unraveling the Complexities of Mesenchymal Stromal Cell-based Therapies: One Size Doesn't Fit All.American journal of respiratory and critical care medicine · 2024
    Article
  7. Article
  8. Article
  9. The Art of Stem Cell-Based Therapy.Advances in experimental medicine and biology · 2023
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Aidan M KirkhamDepartments of Biochemistry, Microbiology & Immunology, University of Ottawa, Ottawa, ON, Canada; Clinical Epidemiology, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Madeline MonaghanClinical Epidemiology, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Adrian J M BaileyClinical Epidemiology, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Risa ShorrMedical Information and Learning Services, The Ottawa Hospital, Ottawa, ON, Canada.
Manoj M LaluCellular and Molecular Medicine, University of Ottawa, Ottawa, ON, Canada; Anesthesiology and Pain Medicine, University of Ottawa, Ottawa, ON, Canada; Clinical Epidemiology, Ottawa Hospital Research Institute, Ottawa, ON, Canada; Regenerative Medicine, Ottawa Hospital Research Institute, Ottawa, ON, Canada; Departments Anesthesia, The Ottawa Hospital, Ottawa, ON, Canada.
Dean A FergussonMedicine, University of Ottawa, Ottawa, ON, Canada; Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada; Clinical Epidemiology, Ottawa Hospital Research Institute, Ottawa, ON, Canada; Medicine, The Ottawa Hospital, Ottawa, ON, Canada.
David S AllanDepartments of Biochemistry, Microbiology & Immunology, University of Ottawa, Ottawa, ON, Canada; Medicine, University of Ottawa, Ottawa, ON, Canada; Clinical Epidemiology, Ottawa Hospital Research Institute, Ottawa, ON, Canada; Regenerative Medicine, Ottawa Hospital Research Institute, Ottawa, ON, Canada; Medicine, The Ottawa Hospital, Ottawa, ON, Canada. Electronic address: daallan@toh.ca.
University of Ottawa · CAOttawa Hospital · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMesenchymal stem/stromal cells (MSCs) and their secreted products are a promising therapy for COVID-19 given their immunomodulatory and tissue repair capabilities. Many small studies were launched at the onset of the pandemic, and repeated meta-analysis is critical to obtain timely and sufficient statistical power to determine efficacy. METHODS AND

findingsAll English-language published studies identified in our systematic search (up to February 3, 2021) examining the use of MSC-derived products to treat patients with COVID-19 were identified. Risk of bias (RoB) was assessed for all studies. Nine studies were identified (189 patients), four of which were controlled (93 patients). Three of the controlled studies reported on mortality (primary analysis) and were pooled through random-effects meta-analysis. MSCs decreased the risk of death at study endpoint compared with controls (risk ratio, 0.18; 95% confidence interval [CI], 0.04 to 0.74; P = .02; I

conclusionUse of MSCs to treat COVID-19 appears promising; however, few studies were identified, and potential risk of bias was detected in all studies. More controlled studies that report uniform clinical outcomes and use MSC products that meet standard ISCT criteria should be performed. Future iterations of our systematic search should refine estimates of efficacy and clarify potential adverse effects.

Indexed as

COVID-19Mesenchymal Stem CellsMesenchymal Stem Cell TransplantationHumansPandemicsSARS-CoV-2acute respiratory distress syndromecoronavirus disease 2019COVID-19exosomesextracellular vesiclesmesenchymal stem cellsmesenchymal stromal cellsmicrovesiclespneumoniaSARS-CoV-2sepsissevere acute respiratory syndrome coronavirus 2

Identifiers

PMID35219584
PMCPMC8802614
OpenAlexW4210501792

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.